We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

48 hedge funds and large institutions have $278M invested in KalVista Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

733% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 3

442% more capital invested

Capital invested by funds: $51.3M → $278M (+$227M)

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

85% more funds holding

Funds holding: 26 → 48 (+22)

14.63% more ownership

Funds ownership: 58.49% → 73.12% (+15%)

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

Holders
48
Holders Change
+22
Holders Change %
+84.62%
% of All Funds
1.1%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.09%
New
25
Increased
9
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$14.3M
2
VMI
VHCP Management II
New York
+$10.3M
3
DM
Deerfield Management
New York
+$8.79M
4
BI
BVF Inc
California
+$8.23M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.12M

Top Sellers

Rank Fund Capital Flow
1
SLG
Stanley-Laman Group
Pennsylvania
-$545K
2
TI
Telemetry Investments
New York
-$529K
3
Deutsche Bank
Deutsche Bank
Germany
-$232K
4
DS
DRW Securities
Illinois
-$167K
5
UBS Group
UBS Group
Switzerland
-$33.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
WMSA
26
Weiss Multi-Strategy Advisers
New York
$884K +$541K +40,000 New
Northern Trust
27
Northern Trust
Illinois
$678K +$415K +30,694 New
Wells Fargo
28
Wells Fargo
California
$598K +$366K +27,068 New
BlackRock
29
BlackRock
New York
$427K +$42K +3,104 +19%
DCM
30
DAFNA Capital Management
California
$392K +$240K +17,725 New
SAM
31
Sectoral Asset Management
Quebec, Canada
$388K +$237K +17,551 New
TI
32
Telemetry Investments
New York
$354K -$529K -39,104 -71%
Two Sigma Investments
33
Two Sigma Investments
New York
$282K +$172K +12,740 New
Dimensional Fund Advisors
34
Dimensional Fund Advisors
Texas
$274K +$167K +12,383 New
SIM
35
Spark Investment Management
New York
$272K -$14.5K -1,072 -8%
VF
36
Virtu Financial
New York
$216K +$132K +9,755 New
Deutsche Bank
37
Deutsche Bank
Germany
$179K -$232K -17,137 -68%
JP Morgan Chase
38
JP Morgan Chase
New York
$124K -$22.3K -1,650 -23%
Morgan Stanley
39
Morgan Stanley
New York
$93K +$46.5K +3,438 +450%
FQ
40
First Quadrant
California
$68K -$20.9K -1,549 -34%
TRCT
41
Tower Research Capital (TRC)
New York
$39K +$19.1K +1,414 +431%
PCM
42
Prelude Capital Management
New York
$15K -$5.11K -378 -37%
UBS Group
43
UBS Group
Switzerland
$14K -$33.2K -2,454 -79%
Bank of America
44
Bank of America
North Carolina
$5K +$3.31K +245 New
VFA
45
Valeo Financial Advisors
Indiana
$3K – – –
Federated Hermes
46
Federated Hermes
Pennsylvania
$3K +$2K +148 New
Barclays
47
Barclays
United Kingdom
$2K +$960 +71 New
AG
48
Advisor Group
Arizona
$1K -$676 -50 -50%
SLG
49
Stanley-Laman Group
Pennsylvania
– -$545K -67,082 Closed
DS
50
DRW Securities
Illinois
– -$167K -20,600 Closed
1
2
3

KALV Hedge Fund Activity: Q3 2018 in Review

48 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2018, worth a combined $278M — up 442% from $51.3M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KALV positions and 3 closed out — a net gain of 22 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Vivo Capital, adding an estimated $14.3M. The largest seller was Stanley-Laman Group, exiting entirely with an estimated $545K sold.

  • 48 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2018, up from 26 in Q2 2018.
  • Funds reported $278M of KalVista Pharmaceuticals stock for Q3 2018, up 442% quarter-over-quarter.
  • 25 funds opened new KalVista Pharmaceuticals positions in Q3 2018 and 3 closed out, a net change of +22 holders.
  • The largest KalVista Pharmaceuticals buyer in Q3 2018 was Vivo Capital, an estimated $14.3M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2018 was Stanley-Laman Group, an estimated $545K sold.

Based on aggregated 13F filings for Q3 2018.